首页> 美国卫生研究院文献>ESMO Open >Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

【2h】

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

机译：具有促进性淋巴瘤激酶抑制剂Ceritinib的精确治疗ALK-REATRANGED anaplastic大细胞淋巴瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

More than 80% of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) patients harbor the (nucleophosmin) NPM1-ALK fusion gene t(2;5) chromosomal translocation. We evaluated the preclinical and clinical efficacy of ceritinib treatment of this aggressive lymphoma.

机译：超过80％的气相生线淋巴瘤激酶（ALK） - 阳性谐波大细胞淋巴瘤（ALCL）患者患有（核磷脂）NPM1-ALK融合基因T（2; 5）染色体易位。我们评估了Ceritinib治疗这种激进淋巴瘤的临床前和临床疗效。

著录项

期刊名称 ESMO Open
作者
V. Subbiah; S. Kuravi; S. Ganguly; D.R. Welch; C.J. Vivian; M.U. Mushtaq; A. Hegde; S. Iyer; A. Behrang; S.M. Ali; R.W. Madison; J.M. Venstrom; R.A. Jensen; J.P. McGuirk; H.M. Amin; R. Balusu;
展开▼
作者单位

展开▼
年(卷),期 2021(6),4
年度 2021
页码 100172
总页数 12
原文格式 PDF
正文语种
中图分类
关键词

机译：精密药;NPM1-ALK + ALCL;ALK抑制剂;凋亡;临床试验;完全反应;

相似文献

外文文献
中文文献
专利

1. Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis [J] . Concetta E. Onesti, Daniela Iacono, Silvia Angelini, Anti-cancer drugs . 2019,第2期

机译：四条血压淋巴瘤激酶抑制剂和脑放射治疗的长杂种非小细胞肺癌，含有百分之肌癌癌激素淋巴瘤激酶阳性患者
2. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand‐1 inhibitor in anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer [J] . Ping Du, Ting Hu, Zhuoling An, Cancer science. . 2020,第6期

机译：体外和体内协同效果的Ceritinib与编程的细胞死亡配体-1抑制剂联合血糖淋巴瘤激酶重排非小细胞肺癌
3. CERITINIB FOR NON-SMALL CELL LUNG CANCER: UNDERSTANDING AND MANAGING ADVERSE REACTIONS FROM THERAPY TARGETING ANAPLASTIC LYMPHOMA KINASE [J] . Kreamer Kristen, Riordan Debbie Oncology nursing forum . 2015,第2期

机译：CERITINIB用于非小细胞肺癌：理解和处理靶向靶向再生性淋巴瘤激酶的治疗的不良反应
4. Functional characterization of ubiquitination profile changes induced by oncogenic protein NPM-ALK in ALK~(+) anaplastic large cell lymphoma cells [C] . Fang Wu, Peng Wang, Raymond Lai, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：致癌蛋白NPM-ALK诱导ubiquitination曲线变化的功能表征Ala1（+）促进大细胞淋巴瘤细胞
5. Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma. [D] . Pearson, Joel Dylan. 2013

机译：了解JunB转录因子在间变性淋巴瘤激酶阳性，间变性大细胞淋巴瘤中的功能。
6. Alectinib an anaplastic lymphoma kinase (ALK) inhibitor as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin [O] . Ritsuko Nakai, Suguru Fukuhara, Akiko Miyagi Maeshima, 2019

机译：Alectinib一种间变性淋巴瘤激酶（ALK）抑制剂可作为同种异体干细胞移植的桥梁适用于对化疗和brentuximab vedotin难治的ALK阳性间变性大细胞淋巴瘤患者
7. ACT-01 THE SECOND GENERATION ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR CERITINIB EFFECTIVELY INDUCES CELL DEATH IN HUMAN GLIOBLASTOMA CELLS [O] . Daisuke Kawauchi, Masamichi Takahashi, Shun Yamamuro, 2019

机译：ACT-01第二代环境保护淋巴瘤激酶（ALK）抑制剂Ceritinib有效地诱导人胶质母细胞瘤细胞中的细胞死亡

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅